Cellular immunotherapy platform
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
106
NCT06528301
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 10, 2025
Completion: Mar 31, 2029
Loading map...